Trial Profile
Phase I trial of LX 2931 as a potential treatment for Duchenne muscular dystrophy
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2013
Price :
$35
*
At a glance
- Drugs ACB2003.4 (Primary)
- Indications Duchenne muscular dystrophy
- Focus Adverse reactions
- 10 Oct 2013 New trial record
- 26 Sep 2013 This trial is expected to be initiated in 2014, according to a CureDuchenne media release.